![132142-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-08/132142-Thumbnail%20Image.png?versionId=oXpsIjPHHocOyDPxqSmTRVVkMuajlJ1o&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240617/us-west-2/s3/aws4_request&X-Amz-Date=20240617T123357Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=fb85c802c3139cbc9324dddf1aaae048cfa76f8abf0179e5018ba08d2a67cfcb&itok=mA5qnbbL)
![131862-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-07/131862-Thumbnail%20Image.png?versionId=ZNFP30clMG0dOJ_7BDzuHfqsLyxPlhYn&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240617/us-west-2/s3/aws4_request&X-Amz-Date=20240617T140949Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=14f9fc2cdaddf339fee7ae8f0b115da28ba174fe04f5c9657863a53ae9f63d17&itok=pSAjvTiv)
![133745-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-05/133745-Thumbnail%20Image.png?versionId=szWy9e7RUZxe902mHSYcAwzExkvPiHdV&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240617/us-west-2/s3/aws4_request&X-Amz-Date=20240617T100753Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=786d0a81c65104fac02482b01e5fed919696322d83d0f9666c2780d5558f0acf&itok=bB6HRLYC)
![158071-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-09/158071-Thumbnail%20Image.png?versionId=0GiQmdTIN1GlXVHUlqMQA_Zs2YLi3Rbm&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240617/us-west-2/s3/aws4_request&X-Amz-Date=20240617T102633Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=0f125f9cf43d7a15df0b8d17b9d5ed56555a03fd30b6c15e2cc9ce27702de213&itok=zCqRcpjH)
![127979-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-04/127979-Thumbnail%20Image.png?versionId=WXS_Z_wO56NDtHGegyG6R_wgk69mrtH.&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240617/us-west-2/s3/aws4_request&X-Amz-Date=20240617T123357Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=7a9de2df849a27a50b2effebd6480692cd5d58c288630393c376e498aeea70a4&itok=gUDPHfWe)
Background: 5-HT1B receptor agonists enhance cocaine intake during daily self-administration sessions but decrease cocaine intake when tested after prolonged abstinence. We examined if 5-HT1B receptor agonists produce similar abstinence-dependent effects on methamphetamine intake.
Methods: Male rats were trained to self-administer methamphetamine (0.1 mg/kg, i.v.) on low (fixed ratio 5 and variable ratio 5) and high (progressive ratio) effort schedules of reinforcement until intake was stable. Rats were then tested for the effects of the selective 5-HT1B receptor agonist, CP 94,253 (5.6 or 10 mg/kg), or the less selective but clinically available 5-HT1B/1D receptor agonist, zolmitriptan (10 mg/kg), on methamphetamine self-administration both before and after a 21-day forced abstinence period during which the rats remained in their home cages.
Results: The inverted U-shaped, methamphetamine dose-response function for intake on the fixed ratio 5 schedule was shifted downward by CP 94,253 both before and after abstinence. The CP 94,253-induced decrease in methamphetamine intake was replicated in rats tested on a variable ratio 5 schedule, and the 5-HT1B receptor antagonist SB 224,289 (10 mg/kg) reversed this effect. CP 94,253 also attenuated methamphetamine intake on a progressive ratio schedule both pre- and postabstinence. Similarly, zolmitriptan attenuated methamphetamine intake on a variable ratio 5 schedule both pre- and postabstinence, and the latter effect was sustained after each of 2 more treatments given every 2 to 3 days prior to daily sessions.
Conclusions: Unlike the abstinence-dependent effect of 5-HT1B receptor agonists on cocaine intake reported previously, both CP 94,253 and zolmitriptan decreased methamphetamine intake regardless of abstinence. These findings suggest that 5-HT1B receptor agonists may have clinical efficacy for psychostimulant use disorders.